Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Puma Biotechnology Inc's Business Segments
Puma Biotechnology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Product
Total Revenue
$ 57
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product0%
- Royalty10.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 96 | - |
| Royalty | $ 6 | 10.3% |
Revenue by Product & Service Category - FY
- Product93.6%
- Royalty6.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 42 | 93.6% |
| Royalty | $ 3 | 6.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- Royalty10.3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 96 | - |
| Royalty | $ 6 | 10.3% |
Description of Puma Biotechnology Inc
Puma Biotechnology Inc. is an American biopharmaceutical company founded in 2010 and headquartered in Los Angeles, California. The company specializes in the development of innovative drugs for the treatment of cancer, with a particular focus on breast cancer, the second most common cancer in women worldwide.
Puma Biotechnology's main product candidate is Neratinib, a small molecule tyrosine kinase inhibitor (TKI) that targets HER2 (human epidermal growth factor receptor 2), a receptor that is overexpressed in approximately 20% of breast cancer patients. HER2 overexpression is associated with more aggressive tumors, higher rates of recurrence, and poorer prognosis.
Neratinib is being developed as an extended adjuvant therapy for patients with HER2-positive early stage breast cancer who have completed standard of care treatment with trastuzumab, another HER2-targeted therapy, and chemotherapy. The extended adjuvant therapy with neratinib is intended to reduce the risk of disease recurrence and improve overall survival.
Puma Biotechnology completed several pivotal clinical trials of neratinib, including the Phase III ExteNET trial, which enrolled over 2,800 patients and demonstrated a statistically significant improvement in disease-free survival compared to placebo. The company has also conducted clinical trials of neratinib in other HER2-positive cancers, including metastatic breast cancer, HER2-mutant solid tumors, and glioblastoma.
In addition to neratinib, Puma Biotechnology has a pipeline of other drug candidates in preclinical and clinical development, including PB272 (neratinib in combination with another TKI), PB357 (a novel kinase inhibitor), and PB891 (an antibody-drug conjugate).
Puma Biotechnology has a global commercialization agreement with Pierre Fabre, a French pharmaceutical company, for the commercialization of neratinib in Europe, Latin America, Africa, and select other countries. The company also has licensing agreements with various academic institutions and biotech companies for the development of its drug candidates.
The company has a market capitalization of approximately $6 billion as of August 2021 and employs approximately 200 people. Puma Biotechnology is publicly traded on the NASDAQ stock exchange under the ticker symbol PBYI.
Puma Biotechnology's main product candidate is Neratinib, a small molecule tyrosine kinase inhibitor (TKI) that targets HER2 (human epidermal growth factor receptor 2), a receptor that is overexpressed in approximately 20% of breast cancer patients. HER2 overexpression is associated with more aggressive tumors, higher rates of recurrence, and poorer prognosis.
Neratinib is being developed as an extended adjuvant therapy for patients with HER2-positive early stage breast cancer who have completed standard of care treatment with trastuzumab, another HER2-targeted therapy, and chemotherapy. The extended adjuvant therapy with neratinib is intended to reduce the risk of disease recurrence and improve overall survival.
Puma Biotechnology completed several pivotal clinical trials of neratinib, including the Phase III ExteNET trial, which enrolled over 2,800 patients and demonstrated a statistically significant improvement in disease-free survival compared to placebo. The company has also conducted clinical trials of neratinib in other HER2-positive cancers, including metastatic breast cancer, HER2-mutant solid tumors, and glioblastoma.
In addition to neratinib, Puma Biotechnology has a pipeline of other drug candidates in preclinical and clinical development, including PB272 (neratinib in combination with another TKI), PB357 (a novel kinase inhibitor), and PB891 (an antibody-drug conjugate).
Puma Biotechnology has a global commercialization agreement with Pierre Fabre, a French pharmaceutical company, for the commercialization of neratinib in Europe, Latin America, Africa, and select other countries. The company also has licensing agreements with various academic institutions and biotech companies for the development of its drug candidates.
The company has a market capitalization of approximately $6 billion as of August 2021 and employs approximately 200 people. Puma Biotechnology is publicly traded on the NASDAQ stock exchange under the ticker symbol PBYI.
Puma Biotechnology Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies specifically for the treatment of cancer. The organization operates through various segments, each with a distinct focus that caters to the needs of cancer patients and healthcare stakeholders. Here’s an extensive overview of the segments, products, and services.
Segments
1. Biopharmaceuticals:
- This is the foundational segment of Puma Biotechnology, engaging in the research, development, and commercialization of cutting-edge cancer therapies. The focus is primarily on early-stage HER2-positive breast cancer and other solid tumors. The company employs advanced scientific approaches and leverages proprietary technologies to address critical gaps in cancer treatment, aiming to bring new therapies to market that can significantly improve patient outcomes.
2. Licensing and Royalties:
- Puma Biotechnology also generates revenue through licensing agreements and royalty streams. When other companies utilize their proprietary technologies or compounds under licensing frameworks, Puma benefits financially from the successful commercialization of those products. This segment not only serves as a revenue-generating avenue but also enables broader access to their innovations through strategic partnerships.
Products
1. Nerlynx (neratinib):
- Nerlynx is the flagship product of Puma Biotechnology. It is an oral therapeutic agent approved for use as an extended adjuvant treatment for adult patients with early-stage HER2-positive breast cancer. As the first FDA-approved extended adjuvant therapy for this patient group, Nerlynx plays a critical role in extending the period of disease-free survival for patients post-surgery. Its approval marked a significant advancement in breast cancer treatment, demonstrating the potential of targeted therapies in improving patient outcomes.
2. PB272 (neratinib):
- PB272 is another formulation of neratinib being investigated for its efficacy in treating metastatic breast cancer and a range of other solid tumors. This compound represents Pumas ongoing commitment to advancing cancer therapies that target underlying cancer biology, and it continues to undergo clinical investigations to determine its full therapeutic potential.
Services
1. Clinical Trials:
- Puma Biotechnology is actively involved in conducting clinical trials. These trials are essential for evaluating the safety, efficacy, and therapeutic potential of new cancer drugs. By engaging patients in clinical trials, Puma not only provides access to innovative treatments that might otherwise be unavailable but also helps to advance scientific understanding of cancer and its various treatment modalities. This process supports the overall goal of bringing new therapies to market that can significantly improve survival rates and quality of life for patients.
2. Patient Assistance Programs:
- Understanding the challenges patients face in accessing medications, Puma Biotechnology has established patient assistance programs. These programs are designed to help eligible patients afford their medications, ensuring that financial constraints do not hinder access to critical treatments. Additionally, Puma provides educational materials and resources to both patients and healthcare professionals to facilitate informed treatment decisions and enhance patient understanding of their conditions and therapies.
Summary
Puma Biotechnology Inc. is committed to addressing the urgent and unmet needs of cancer patients through its innovative drug development efforts. The companys segments encompass both the research and commercial aspects of biopharmaceuticals, while its products—particularly Nerlynx and PB272—illustrate its dedication to improving outcomes in cancer treatment. Through robust clinical trial programs and supportive patient assistance initiatives, Puma strives to make a lasting impact in the oncology landscape, enhancing the lives of patients affected by cancer.
Segments
1. Biopharmaceuticals:
- This is the foundational segment of Puma Biotechnology, engaging in the research, development, and commercialization of cutting-edge cancer therapies. The focus is primarily on early-stage HER2-positive breast cancer and other solid tumors. The company employs advanced scientific approaches and leverages proprietary technologies to address critical gaps in cancer treatment, aiming to bring new therapies to market that can significantly improve patient outcomes.
2. Licensing and Royalties:
- Puma Biotechnology also generates revenue through licensing agreements and royalty streams. When other companies utilize their proprietary technologies or compounds under licensing frameworks, Puma benefits financially from the successful commercialization of those products. This segment not only serves as a revenue-generating avenue but also enables broader access to their innovations through strategic partnerships.
Products
1. Nerlynx (neratinib):
- Nerlynx is the flagship product of Puma Biotechnology. It is an oral therapeutic agent approved for use as an extended adjuvant treatment for adult patients with early-stage HER2-positive breast cancer. As the first FDA-approved extended adjuvant therapy for this patient group, Nerlynx plays a critical role in extending the period of disease-free survival for patients post-surgery. Its approval marked a significant advancement in breast cancer treatment, demonstrating the potential of targeted therapies in improving patient outcomes.
2. PB272 (neratinib):
- PB272 is another formulation of neratinib being investigated for its efficacy in treating metastatic breast cancer and a range of other solid tumors. This compound represents Pumas ongoing commitment to advancing cancer therapies that target underlying cancer biology, and it continues to undergo clinical investigations to determine its full therapeutic potential.
Services
1. Clinical Trials:
- Puma Biotechnology is actively involved in conducting clinical trials. These trials are essential for evaluating the safety, efficacy, and therapeutic potential of new cancer drugs. By engaging patients in clinical trials, Puma not only provides access to innovative treatments that might otherwise be unavailable but also helps to advance scientific understanding of cancer and its various treatment modalities. This process supports the overall goal of bringing new therapies to market that can significantly improve survival rates and quality of life for patients.
2. Patient Assistance Programs:
- Understanding the challenges patients face in accessing medications, Puma Biotechnology has established patient assistance programs. These programs are designed to help eligible patients afford their medications, ensuring that financial constraints do not hinder access to critical treatments. Additionally, Puma provides educational materials and resources to both patients and healthcare professionals to facilitate informed treatment decisions and enhance patient understanding of their conditions and therapies.
Summary
Puma Biotechnology Inc. is committed to addressing the urgent and unmet needs of cancer patients through its innovative drug development efforts. The companys segments encompass both the research and commercial aspects of biopharmaceuticals, while its products—particularly Nerlynx and PB272—illustrate its dedication to improving outcomes in cancer treatment. Through robust clinical trial programs and supportive patient assistance initiatives, Puma strives to make a lasting impact in the oncology landscape, enhancing the lives of patients affected by cancer.